IBRX FY 2015 Earnings — ImmunityBio, Inc. Revenue & Financial Results | Market Cap Arena

IBRXImmunityBio, Inc.

$8B

FY 2015 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$236,000-63.2% YoY

Gross Profit

$236,000100.0% margin

Operating Income

-$239M-101218.6% margin

Net Income

-$237M-100371.2% margin

EPS (Diluted)

$-0.73

Cash Flow

Operating Cash Flow

-$25M

Free Cash Flow

-$28M

Stock-Based Comp.

$211M

Balance Sheet

Total Assets

$367M

Total Liabilities

$11M

Stockholders' Equity

$356M

Cash & Equivalents

$176M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$236,000	$641,000	-63.2%
Gross Profit	$236,000	$641,000	-63.2%
Operating Income	-$239M	-$6M	-3745.4%
Net Income	-$237M	-$6M	-3712.6%